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Abstract 
Background: Mammography is the current standard for breast cancer detection however 
magnetic resonance imaging (MRI) is a more sensitive method of breast imaging. Despite MRI’s 
increased sensitivity, MRI has more false positives and higher costs. The purpose of this study 
was to determine if MRI or MRI in conjunction with mammography was a cost-effective 
solution for breast cancer detection in women with average lifetime risk of breast cancer.  
Methods: A mathematical model was used to compare annual mammography, annual MRI, and 
mammography and MRI on alternate years. The model included the natural history of breast 
cancer, screening by mammography and MRI, screening and treatment costs, and health state 
utilities. The Surveillance, Epidemiology, and End Results project provided data for the natural 
history model.  Data from the Breast Cancer Surveillance Consortium and from the literature was 
used to model screening.  Costs were taken from the Physician Fee Schedule for Medicare and 
Medicaid Services (CMS) and from the literature. In particular, mammograms were priced at  
$81.35 each and MRIs were priced at $787.23 each. Utilities for stages of breast cancer were 
found using Tuft University Cost Effectiveness Analysis Registry 
Results: The difference between MRI only and mammography only was $842,297/QALY at the 
standard cost of screening found from the CMS. The difference between MRI plus 
mammography and mammography only was $749,131/QALY at standard CMS screening costs. 
Discussion: Although MRI may have health benefits, at current prices, MRI screening is not a 
cost-effective alternative to annual mammography in women age 40 to 80 with average risk of 
breast cancer. MRI’s would cost effective at a $50,000 per QALY level if the cost of MRI 
screening were comparable to that of mammography.  
Background 
The most common cancer affecting women in the western world is breast cancer 1. 
Because of the volume of women affected by this cancer, certain methods must be developed to 
detect and prevent the spread of breast cancer. Methods for the latter include surgical operations 
such as bilateral mastectomy or chemoprevention with the use of tamoxifen and related drugs. 
Methods for the detection include clinical surveillance, ultrasound, mammography and magnetic 
resonance imaging (MRI). The tests developed to detect breast cancer are rated by sensitivity and 
specificity. Sensitivity relates to the tests ability to identify positive results (cancers). Specificity 
relates to the ability of the test to identify negative results (non-cancers). Mammography, with a 
relatively high sensitivity level, has been proven to reduce mortality rate in women with breast 
cancer 2. 
 Although breast cancer is usually considered a sporadic disease, women with familial or 
hereditary breast cancer may carry a breast cancer susceptibility gene BRCA mutation which can 
give them up to 60-80% lifetime risk of breast cancer1.  Prophylactic bilateral mastectomy 
appears to be the most effective way to prevent breast cancer in women who have a high risk of 
breast cancer1.  Even for women with a BRCA gene mutation, the decision for a mastectomy is 
difficult because of the emotional and mutilating effects. Current national guidelines do not 
recommend mastectomy as a standard procedure for all women with BRCA gene mutation2. 
Current aggressive surveillance practices for high risk women consist of mammogram and 
physical examination every 6 to 12 months beginning at age 253.  
Magnetic Resonance Imaging (MRI) is an option for women at high risk of breast cancer. 
MRI’s have a higher biopsy rate but help to detect more cancers than mammography4. 
HIBCRIT’s study on Italian women concluded that the addition of magnetic resonance imaging 
to current screening regimen for women in the high risk category may enable the detection of 
breast cancers that may have otherwise been missed5. MRI’s are also beneficial because 
mammography is affected by breast density causing mammography tests to be less effective on 
young women with denser breasts. Another advantage of MRI screening is unlike 
mammography, the MRI test does not use ionizing radiation. MRI screening for breast cancer 
has been deemed to be impractical for use on the general population (women without high 
hereditary risk or BRCA gene mutations) because of its high cost and limited availability5. MRI 
also has a low specificity rate leading to further tests and more money being spent.  
Studies have been conducted to determine whether regular MRI screening has been 
effective in high risk women. In a study by Moore et al, research found that although there may 
be health benefits to using MRI’s, it does not appear to be cost effective at a willingness to pay 
thresholds greater than 120,000/quality-adjusted life years (QALY) 6. A similar study was 
conducted by Plevritis et al. in BRCA1/2 carriers. Plevritis et al. found that in that population, 
MRI along with mammography is cost-effective compared to mammography alone. However, 
the results vary greatly with age 7.  
It is now current scientific consensus that woman with a BRCA1 or BRCA2 mutation 
undergo MRI in addition to mammography8. However, little is known about the cost 
effectiveness of using MRI surveillance in women without an extremely elevated risk (45-65% 
lifetime risk) 6. It is this segment of the population with an average risk of developing breast 
cancer that on which we conducted our research. 
Methods 
 We created a mathematical model in an effort to determine the cost-effectiveness of 
magnetic resonance imaging (MRI) versus mammography. In order to create a computer 
simulation capable of determining this cost-effectiveness, we researched many factors about 
breast cancer natural history and screening. Key factors include survivability, tumor size, 
sensitivity and specificity of screening methods, utility weights based on quality of life years 
(QALY), and cost of treatment.  
Sensitivity and Specificity of Mammography and MRI Screening 
To determine sensitivity and specificity, three studies were chosen because they were 
split into first and subsequent MRI tests that were rated on the same BIRAD scale of 3+. These 
three studies were conducted by Dr. Martin Leach and the MARBIS study group in 2005, Dr. 
Mike Kriege in 2004, and Dr. Ellen Warner in 20042, 8, 9.Table 1 below gives a description of 
these findings. 
Table 1 
Study Kreige  Warner  Leach   
 First Subsequent First Subsequent First Subsequent  
Sens  MRI .79 .62 .83 .67 .75 .67  
Sensmamm .38 .43 .38 .43 .40 .40  
Spec MRI .87 .92 .93 .98 .82 .81  
Spec mamm .94 .95 .100 .100 .94 .95  
# of MRI screens 1909 2260 236 221 649 1232  
# of mamm screens 1909 2260 236     221   649 1232  
Total # of cancers 24 21 13 9 20 15  
True positives MRI 19 13 11 6 15 12  
True positive mamm 9 9 5 3 8 6  
False negative MRI 5 8 2 3 5 3  
False negative mamm 15 12 8 6 12 9  
False positive MRI 245 179 15 5 113 231  
False positive mamm 113 112 1 0 4 73  
True negative MRI 1640 2059 208 207 516 986  
True negative mamm 1772 2127 222 222 585 1144  
Found on both 22 19 4 2 427 35  
Found in interval 2 3 1 2 1 1  
        







Table 2 consolidates this data by taking the sums and weighted averages of the 
information in Table 1. 
Table 2 
   
 First Subsequent 
Sens  MRI .79 .67 
Sensmamm .39 .40 
Spec MRI .86 .88 
Spec mamm .94 .95 
# of screens 2794 3713 
Total # of cancers 57 45 
True positives MRI 22 18 
True positive mamm 9 9 
False negative MRI 12 14 
False negative mamm 35 27 
False positive MRI 373 415 
False positive mamm 113 112 
True negative MRI 1640 2059 
True negative mamm 158 185 
Found on both 453 56 
Found in interval 4 6 
False pos rate MRI 0.134 0.112 
False pos rate mamm 0.057 0.049 
   
   
Incidence 
Surveillance Epidemiology and End Results, SEER10, allowed us to see the ages, races 
and ethnicities that were most prone to developing breast cancer. We used the equation:  
where x represented age t and y represented incidence per 100,000 people. We fit the parameters 
a, b and c to the SEER data stratified by age and ethnicity. 
Growth of Breast Tumors 
( )cbxaxy ++= 2exp
We used a modified exponential growth model to describe tumor growth. Growth was 
modeled by the equation     exp	
, where k represented the growth parameter that was 
ln(2)/doubling time and was the volume at the time of detection by symptoms. In this modified 
version of the exponential growth model, the median doubling time increased with age, 
according to the equation   	0.021  2.3 , where x was age (in years) and y represented 
doubling time (in years)11. Each woman has their own doubling time curve based off of a random 
number drawn from a lognormal distribution. The growth parameters were chosen to match 
detection rates from the Breast Cancer surveillance Consortium12. The distribution of tumor sizes 
at the time of detection by symptoms came from SEER, year 198310. We then assigned a random 
number to each woman to determine her tumor size at the time of detection. Within the model 
tumors may also be detected at a smaller size by screening using either a mammogram or MRI. 
Detection of Breast Cancer  
 By Symptoms - The probability of getting breast cancer by age t was given by the 
equation 	  1  exp   	 

  , where h	x is the incidence by age curve. Based on 
the model each woman was given a random number r ranging from 0 to 1, representing her 
susceptibility of acquiring breast cancer. Her age of diagnosis of breast cancer by symptoms was 
represented by the age t at which P (t) = r. A woman with a random number closer to 0 would 
mean that she would acquire breast cancer at a much earlier age. However, a woman with a 
random number closer to 1 acquired breast cancer later on in age or not at all.   
 By Mammograms– The model assumes the probability of detecting a tumor on a 
mammogram depends on the tumor size and the mammographic density of the breast. We use the 
equation 	-  1  exp	.1  -/, to represent the probability of detecting a tumor on a 
mammogram. The variable s represents the tumors diameter in millimeters (mm), P(s) represents 
the probability of detecting the tumor on a mammogram and a1 represents a parameter of women 
with dense breasts; based on women in their 40’s13. Women in this age group have an average 
breast density of 40% dense tissue13. We then used a separate parameter a2 based of BCSC data 
for women in their 60’s, which have an average breast density of 25% dense tissue12. To 
calculate probability of women from other age groups, we took the average breast densities for 
the ages of these women and linearly interpolated between the two probability equations.  
 MRI’s– Similarly to mammograms, we assumed that the probability of detection 
increases with tumor size and used the equation 	-  1  exp	.3  -/. We fit this 
parameter to sensitivity data from three analysis that reported on data incidence and prevalence 
in high risk women undergoing mammograms and MRI’s5, 8, 14.Details about the sensitivity and 
specificity analysis can be seen in Table 1 and Table 2. 
Survival 
 We assumed that the probability of survival from breast cancer decreased with increasing 
tumor size. The rate that survival decreased depended on the time since detection and varied by 
race and ethnicity. R Studio used to carry out a proportional hazard analysis; stratified by both 
race and ethnicity, with the natural log of the tumor diameter 15. We obtained information on 
tumor size from SEER; data set 18 from years 1988 – 200310. For tumors of average size we 
modeled survival with the equation  exp 	01231, where x is the time since diagnosis and y is 
the probability of survival. The relative risk of dying as a function of tumor size was given by the 
equation rr = exp(beta*(ln(diameter) – mu)), where mu was the average of ln(diameter) at 
detection, and beta represents the coefficient from the proportional hazards model. The final 
equation for survival was P = exp((a*x + b)/(c*x + 1))^exp (beta*(ln(diameter) – mu)). 
Mortality 
 We went to the Centers for Disease Control (CDC) website and selected data from 2001 
– 2010, using 5 year age groups, stratified by gender, race16. Using Excel and R Studio we 
graphed the mortality and fit the equation: ; where x represented age and y represented 
mortalities per 100,000.  
A similar process was used to determine mortality from other causes. We fit an 
exponential curve to the CDC data for breast cancer mortality for women, stratified by race. The 
data set that we obtained this information from was CDC years 2001 – 201016. The equation that 
we set the information to was   .  exp	45 with age represented byx and breast cancer 
deaths per 100,000 women represented by y. Parameters a and b depended on gender, race and 
origin. Mortality from other causes besides breast cancer is the difference between mortality 
from all causes and mortality from breast cancer.  
Utility Weights 
To determine an accurate set of utility weights we went to the Tuft University Cost 
Effectiveness Analysis (CEA) Registry17and used the basic search with the search term “breast 
cancer” with the utility weights clicked. Over 20 pages of utility weights matched our search. 
Each utility weight from 2003 onward was analyzed and ranked according to how relevant it was 
to how we wanted our model to be set up, which was by stages of breast cancer or by the time 
since diagnosis. The article by Dr. Schousoe which divided up the cancers into stages and first 
year vs. subsequent years seemed to be most conducive to the goals of our simulation because 
these factors significantly affected the cost of treatment 18. Schousboe’s article referenced 
another article, “Health related Quality of Life in Different States of Breast Cancer”, by Dr. 
Lidgren19. Ledgren’s article surveyed individuals in a time trade off scenario as well as an EQ-
5D model. We chose our utilities for our simulation to be the means from the EQ-5D model. The 
means for first year after primary breast cancer, subsequent years of primary breast cancer and 
metastatic diseases were .686, .776, and .689 respectively 19. 
Cost of Treating Breast Cancer 
To find the cost of treating breast cancer we did a Google Scholar search with the term 
‘Cost of treating breast cancer in the United States’20.  The most promising result was a review 
article by Dr. Campbell titled, “The costs of treating breast cancer in the US: a synthesis of 
published evidence”21. This article yielded Table 3. Campbell’s article reviewed and compiled 8 
different studies based on cost of treating breast cancer in the initial 6 months, continued 
treatment and terminal 6 months of breast cancer. Because many of these studies are dated and 
the currency is not equivalent each section was put into the perspective of 2012 United States 
dollars (USD) by using “Tom’s Inflation Calculator”22which is based on the Consumer Price 
Index 23. To find each value in 2012 USD, the cost at the base line year, the base line year, and 
2012 were entered in the calculator along with highlighting the option of ‘U.S Medical Inflation 
(1935-2012)’.  Each value was recorded in Table 2. The medians for the cost of initial 6 months 
of treatment was were $20,821.31, the cost of continued treatment per 6 months was $4,445.72 
and the cost of 6 months prior to termination was $63,202.45. In this simulation, the cost of 






     
Study Year Initial Subsequent Final 
Baker 1984 6,663.98   33,583.70 
Tplin 1989 25,965.56 1,504.68   
Legorreta 1989 20,821.31     
Riley 1990 22,700.96 3,993.61 128,488.50 
Fireman 1992 32,151.08 4,897.82 76,973.22 
McDonough 1995 17,099.24 9,130.88 69,683.64 
Barnett 1997     151,767.69 
Barlow 1998 14,561.92   56,721.26 
Warren 1998 12,175.48   40,293.69 
Lamerato 2003 57,237.53   33,070.72 
Median  20,821.31 4,445.72 63,202.45 
     
**Note: Initial refers to cost in USD for the first 6 months of diagnosis, Subsequent refers to cost 
of continuing treatment in USD for 6 month intervals and Final is the cost of treating the last 6 
months on life in USD. 
 
Cost of Mammography and MRI screening 
To determine the cost of mammography and MRI screening, the Physician Fee Schedule 
Search from the Centers of Medicare and Medicaid Services (CMS) was employed24. In the 
Physician Fee Schedule Search the criteria we used was 2012A year, pricing information, single 
Healthcare Common Procedure Coding System (HCPCS) or Current Procedural Terminology 
(CPT) code, all carriers, the corresponding HCPCS code for the individual test and all modifiers. 
The search yielded a cost for a digital mammography screening test $81.35 and the cost for MRI 
screening to be $787.23. The corresponding HCPCS/CPT numbers were 77057 and 7705 
respectively.  
Using the R-Studio simulation 
To create a computer simulation able to run clinical trials on groups of 100,000 women 
the computer software R Studio was used 15. Into the input 3 arms were created each running 
simulated cohorts of 100,000 women. In these arms future cost and QALYs were discounted by 
a factor of 0.03. In the first arm the simulation gave women a mammogram every year from age 
40 to 80 which is the current recommendation for women that have an average risk of developing 
breast cancer in their lifetime 3. The second arm is using MRI screening only from age 40 to age 
80.  Arm 3 alternates between mammography and MRI every year from age 40 to 80. These 
arms were simulated using the actual cost of mammography and MRI and then used adjusted 
costs to determine the price for MRI screening that would make it cost-effective compared to 
mammography in terms of cost per QALY. All other variables remained the same throughout the 
tests 
Results 
Each clinical trial consisted of three arms. Arm 1 is mammography only from 40 to 80 
yearly, arm 2 is MRI only from 40 to 80 yearly, and arm 3 is mammography and MRI alternating 
years from 40 to 80. “Number” on the y-axis refers to the difference in the number of QALYs 
and “Time” refers to years.  MRI screening was able to preserve QALYs however it proved to be 











Figure 1                                                                                    
 
 
Figure 1 shows how when screening begins at age 40, the trials with MRI (Arm 2) only 
and MRI and mammogram (Arm 3) drop lower than the QALYs of the trial of mammography 
only (Arm 1). This can be explained by MRI’s detecting more cancers in younger women, and 
when these women discover they have cancer their QALYs lower form 1to what was discovered 
in our utility weights for first year after primary breast cancer to be .686 19.However, as time 
goes on and more breast cancers are being discovered by the mammogram only trial and less 
metastatic cases are present in the MRI and MRI and mammogram trial, these QALY’s end up 
being higher when being compared to the mammography only arm. The MRI only arm reaches 






The costs in Figure 2 demonstrate how MRI only (Arm 2) is more expensive than MRI 
and mammography (Arm 3) and mammography only (Arm 1). The costs begin to differentiate 
themselves at age 40 when the screening begins and stay steadily different until age 80 when 
screening ends.  
 
We used the incremental cost-effectiveness ratio (ICER) in an effort to compare 
screening strategies of MRI and mammogram. Our ICER was the difference between costs 
divided by the difference of QALY. The comparison of ICER values for differing prices of MRI 




MRI only vs. mammography 
only 
MRI and mammogram vs. 
mammography only 
 Cost QALY ICER Cost QALY ICER 
Standard Costs** 14984 0.018 842,297 7458 0.010 749,131 
MRI 2x cost of mamm 2018 0.018 113,452 1094 0.010 109,863 
MRI 1.5x cost of mamm 1174 0.018 65,990 679 0.010 68,234 
MRI same cost as mamm 329 0.018 18,515 265 0.010 26,593 
       
*Sample consists of 100,000 individuals each arm 
**Standard costs are $81.35 per mammogram and $787.23 per MRI 
 
The ICER value decreases as the cost of MRIs decreases. This is logical because as the 
difference in cost of MRIs decreases, the total breast cancer cost decreases and the difference in 
QALYs is not affected by cost.  
Table 5 
 BC* diagnosed BC deaths False Positives 
Mammography only 0.116 0.018 2.80 
Mammography and MRI 0.117 0.016 3.58 
MRI only  0.118 0.015 3.83 
    
*breast cancer 
**Result per person 
***Sample consists of 100,000 individuals in each arm 
 
The use of MRI screening allows for more diagnoses of breast cancer and less deaths by 
breast cancer. However, the number of false positives in the mammogram only trial is less that 























Mammogram only Standard Cost** 1693/ 20 900 / 11 3985 / 47 1868 / 22 8447 
Mammogram only Same Cost*** 1693 /  20 900 / 11 3985 / 47 1868 / 22 8447 
MRI and Mammogram Standard Cost 8897 / 56 1108 / 7 4028 / 25 1872 / 12 15904 
MRI and Mammogram Same Cost 1705 /  20 1108 /  13 4028 / 46 1872 / 21 8711 
MRI only Standard Cost 16344 / 70 1161 / 5 4053 / 17 1873 / 8 23431 
MRI only Same Cost 
 
1689 / 19 1160 / 13 4053 / 46 1874 / 21 8777 
      
*data based on dollars per person of 100,000 sample 
** Standard screening costs are $81.35 per mammogram and $787.23 per MRI 
***Same cost were $81.35 per mammogram and $81.35 per MRI 
 
For the use of mammography screening only, the primary cost involved is the cost of 
treatment. However, when MRI is used alone or with mammography screening the major cost is 
the screening. The cost of MRI screening is causing a large cost difference between 
mammography screening and MRI plus mammography and MRI alone. Note that even when 
MRIs cost the same as mammograms, the MRI arm has higher total costs than the mammogram 
arm. This is primarily due to the increased number of false positives that are associated with 
MRI’s and partially due to MRI’s ability to detect more breast cancers earlier and therefore 
increasing the treatment costs.  
Discussion 
Although MRI may have health benefits, based on a $100,000/QALY cost effectiveness 
ratio, current prices of MRI do not support that MRI screening for women yearly from ages 40 to 
80 or alternating between mammography and MRI yearly for women of the same ages as cost 
effective. However, if the costs of MRI were able to come down to twice the current price of 
mammography, the ICER value suggests that at a $100,000/QALY threshold, alternating MRI 
and mammography screening would be cost effective. With MRI prices equal to mammography 
prices, MRI alone as well as MRI with mammography screening would be cost effective even at 
a $50,000/QALY ratio.  
Our findings are similar to those of Susan G Moore in her 2009 study which found that 
MRI screening is not cost effective at current MRI price. However, our study does not deal with 
a young age population or with individuals of pre-determined high risk. Other studies such as 
Pleuvertis 2006 and Lee 2010, also dealing with high risk categories, however, found the 
practice of MRI screening to be cost effective in specific cases.  
Weaknesses in our analysis could include that the specificity and sensitivity of our 
screening techniques were determined by studies of women of high risk. The sensitivity and 
specificity of these tests for women on the typical population could be different. Another 
weakness in our model could be the utility weights. The current utility weights indicate that the 
first year of being diagnosed with breast cancer is nearly equal to the metastatic stage which does 
not seem intuitive.  
Future directions of study include what level of risk makes MRI cost-effective. Since 
MRI is not cost-effective for the entire population it may be useful to know what category of 5-
year risk would make MRI’s cost effective. Sensitivity analysis could be conducted to see the 
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